Specialty Pharmacy

FDA Approves Neurocrine’s Once-Daily Ongentys as an Add-On Treatment for Parkinson’s Disease Patients Experiencing “Off” Episodes

SAN DIEGO – April 27, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral ONGENTYS® (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. As the disease …

Read More »

Data on 53 Patients Treated with Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in NEJM

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an individual compassionate use basis. The majority of patients in this international cohort demonstrated clinical improvement and …

Read More »

Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced that its Phase II exploratory NAFLD/NASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile. …

Read More »

Axsome Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in its Phase 3 Trial

NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07 substantially and significantly eliminated migraine pain, and substantially and significantly prevented progression of migraine pain intensity in …

Read More »

Biohaven Achieves Positive Results in Pivotal Trial of Oral Nurtec for the Preventive Treatment of Migraine

NEW HAVEN, Conn., March 30, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg for the preventive treatment of migraine in both episodic and chronic migraine …

Read More »

Engage Therapeutics Announces Phase 2b Study of Staccato Alprazolam for Seizure Cessation Meets Primary Endpoint

SUMMIT, N.J., March 12, 2020 (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure …

Read More »

CVS Pharmacy to Acquire Schnuck Markets Retail and Specialty Pharmacy Businesses

WOONSOCKET, R.I., March 10, 2020 /PRNewswire/ — CVS Pharmacy, Inc., a subsidiary of CVS Health Corporation (NYSE: CVS), and Schnucks announced today that they have entered into a definitive agreement for CVS Pharmacy and certain of its subsidiaries to acquire Schnuck Markets Inc.’s retail and specialty pharmacy businesses. Through this …

Read More »

FDA Approves Allergan’s Durysta, a Long-Term Eye Implant for Patients with Glaucoma or Ocular Hypertension

DUBLIN, March 5, 2020 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for …

Read More »

KabaFusion Acquires Lincare’s Infusion Pharmacies, Expanding Patient-Focused Home Infusion Services Nationwide

CERRITOS, Calif.–(BUSINESS WIRE)–KabaFusion, a leading provider of specialty acute and chronic home infusion therapies, today announced it has acquired the home infusion assets of Lincare, a subsidiary of Linde plc. The strategic combination strengthens KabaFusion’s position as the premier clinician-led home infusion company in the United States, significantly enhancing the …

Read More »

Biohaven’s Nurtec Receives FDA Approval for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first FDA-approved product for Biohaven, a company dedicated …

Read More »